On 7 July 2025, the European Commission launched a public consultation that could mark the start of a turning point for how Artificial Intelligence (AI) is used in pharmaceutical manufacturing. The consultation proposes significant updates to the EU Good Manufacturing Practice (GMP) guidelines—specifically Chapter 4 on Documentation, Annex 11 on Computerised Systems, and, for the first time, a new Annex 22 dedicated to AI.
More Posts
European Data Protection Board publishes study on secondary use of personal health data for scientific research
The Convergence of Life Sciences and Artificial Intelligence: Seizing Opportunities While Managing Risk
EMA adopts reflection paper on the use of Artificial Intelligence (AI)
AI: EMA publishes guiding principles on the use of large language models (LLMs)
The EU AI Act: Impact on the Life Sciences Industry
Commission Communication on biotechnology and biomanufacturing
Subscribe: Subscribe via RSS
Blogs
Firm/Org